| CAS NO: | 1494675-86-3 |
| 包装 | 价格(元) |
| 2mg | 电议 |
| 5mg | 电议 |
| 10mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| Cas No. | 1494675-86-3 |
| 别名 | N-(2-羟基乙基)-1-[(6-甲氧基-5-甲基嘧啶-4-基)甲基]-6-甲基-1H-吡咯并[3,2-B]吡啶-3-甲酰胺 |
| Canonical SMILES | O=C(C1=CN(CC2=NC=NC(OC)=C2C)C3=CC(C)=CN=C31)NCCO |
| 分子式 | C18H21N5O3 |
| 分子量 | 355.39 |
| 溶解度 | DMSO : 11 mg/mL (30.95 mM) |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | DprE1-IN-1 is a potent DprE1 inhibitor, with ic50 of 10 nM, also inhibits PDE6, with IC50 of 6 uM.IC50 value: 10 nM [1]Target: DprE1in vitro: DprE1-IN-1 demonstrats efficacy in a rodent model of tuberculosis, making it promising for further development.[1]in vivo: The pharmacokinetic profile of DprE1-IN-1 as a representative of the series in mice, rats, and dogs was determined after i.v. and oral dosing. DprE1-IN-1 shows oral bioavailabilities of 86% and 100% in rats and dogs, respectively. The oral exposures of DprE1-IN-1, assessed in infected animals, shows AUCs ranging from 166 to 240 uM . h, and free plasma concentrations were maintained above the MIC for 10 to 24 h. [2] References: |
m.cnreagent.com